Peptide blend of BPC-157 and TB-500, studied for soft-tissue and injury recovery.
This is a combination sold as one vial. It has not been studied as a single substance, so what is known is what is known about each part, linked above. Sources that report a dose for the blend report it for that mixture, not for any component on its own.
We have not published an audit on Wolverine. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
Pairs BPC-157 and TB-500 repair peptides; studied for soft-tissue and injury recovery.
BPC-157 targets local tissue repair signaling (angiogenesis, growth factors) at the injury site, while TB-500 works systemically to promote cell migration and mobilization, with the two compounds hypothesized to cover non-overlapping repair pathways.
No long-term human safety data exists for this stack; reported issues include mild injection-site reactions (redness, swelling, bruising), anecdotal lethargy or head-pressure with TB-500 loading, a theoretical cancer/angiogenesis concern, and quality-control risks from unregulated suppliers.
People with active or undiagnosed cancer and athletes subject to WADA/USADA testing should avoid this stack, as both compounds are prohibited and carry a theoretical angiogenesis-related tumor risk.
Blood tests are mentioned (SiPhox Health At-Home Blood Test is listed as a recommended supply), but no specific labs or monitoring parameters are named on the page. [Source: peptidedosingprotocols.com]
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Wolverine or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| 1.0 mg total blend daily (0.5 mg of each compound) from a pre-blended 20 mg vial. | not stated | not stated | Peptide Dosing Protocols stackWhat it saysHide(secondary reference; provider confirmation required). |
| Pre-blended: 0.5-2.0 mg total blend daily (0.25-1.0 mg BPC-157 + 0.25-1.0 mg TB-500); Separate vials: BPC-157 250-500 mcg daily, TB-500 2.0-5.0 mg 2x/week (loading), TB-500 2.0 mg 1-2x/week (maintenance) | Pre-blended: daily; Separate vials: BPC-157 daily, TB-500 2x/week (loading) or 1-2x/week (maintenance)6-12 weeks total; loading phase weeks 1-4, maintenance phase weeks 5-8 or 5-12 depending on protocol; off-cycle gaps of 2-4 weeks commonly described | subcutaneous | peptidedosingprotocols.comWhat it saysHide(secondary reference; provider confirmation required). [Source: peptidedosingprotocols.com] |
The Wolverine Stack is a community shorthand for pairing two research peptides — BPC-157 and TB-500 — into one tissue-repair-focused protocol. It is not an FDA-approved treatment and not a clinical designation. The name comes from the comic-book character known for fast healing.
Two community-derived dosing models dominate. Pre-blended vial: 0.5–2.0 mg total of a 1:1 BPC-157 + TB-500 blend daily for 6–12 weeks. Separate vials: BPC-157 250–500 mcg daily plus TB-500 2–5 mg twice weekly during loading, with a tapered 8–12 week cycle. These are research-planning structures, not dosing recommendations.
Pre-blended is simpler — one vial, one daily injection, locked 1:1 ratio. Separate vials let BPC-157 and TB-500 run on independent schedules (most often daily BPC-157 + twice-weekly TB-500 loading) and allow independent dose tuning. Both formats deliver the same compounds; the trade-off is convenience versus control.
There is no published human safety dataset for the combination. Compound-level reports from animal studies and small human exposure data describe low acute toxicity; the most common reported issue is injection-site reaction (redness, mild swelling, transient bruising). The most-cited theoretical concern is angiogenesis: both compounds promote new blood vessel formation, which is the intended repair mechanism but also a pathway relevant to tumor growth.
Animal studies and a small open-label human knee-pain case series (Vasireddi et al. 2025 systematic review, HSS Journal) reported no serious adverse events. There is no published long-term human safety data, no completed RCT, and the most-cited theoretical concern remains angiogenesis in the context of undiagnosed cancer. Quality of unregulated supply is also a real, separate risk.
No. As of June 2026, neither compound is FDA-approved. Both were removed from FDA 503A Category 2 on April 22, 2026, but neither is on Category 1 either. PCAC will evaluate both compounds on July 23, 2026, after which FDA will issue a 503A bulks-list determination. Both remain WADA-prohibited.
Most community-derived protocols run 6–12 weeks total. A common separate-vial structure is 4 weeks of loading followed by 4–8 weeks of maintenance dosing. Pre-blended protocols often run a steady daily dose for the full cycle without a distinct loading phase. Off-cycle gaps of 2–4 weeks are commonly described but not formalized in any published trial.
No published trial — preclinical or human — has tested the combination. The synergy argument is mechanistic, based on non-overlapping pathways for local repair (BPC-157) and systemic cell migration (TB-500). Compound-level evidence does not validate the combination.
The reference sections above are imported from our compound knowledge base, which classes the evidence for Wolverine as emerging. That classification is the knowledge base’s, not ours, our own grade appears only where an audit is linked above. Research use only; nothing here is medical advice or a protocol.
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. Studied in tissue-repair and regeneration research models.
Peptide blend of GHK-Cu, BPC-157, and TB-500, studied for skin quality, tissue repair, and recovery.
5-Amino-1MQ is a small molecule studied for its potential to help the body shrink fat cells and raise NAD+ levels without cutting appetite.
Peptide bioregulator referenced for connective tissue support.
Peptide bioregulator referenced for nervous system support.
Combination research blend of CJC-1295 (no DAC) and Ipamorelin. Studied as a GHRH/GHRP combination in growth-hormone-axis research.